On October 06, 2026, BridgeBio Pharma Inc...announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for oral infigratinib, targeting achondroplasia, and granted it Priority Review status. (Gurufocus) - Oct 6, 2026 - "The FDA's decision is expected by February 4, 2027."
FDA filing • PDUFA • Priority review • Genetic Disorders
|